How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

164 results for

Metrorrhagia Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Metrorrhagia Management

Metrorrhagia Management Metrorrhagia Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Metrorrhagia Management Metrorrhagia (...) Management Aka: Metrorrhagia Management , Anovulatory Bleeding Management From Related Chapters II. Indication ( ) III. Goal: Correct Unopposed Estrogen Prevent Prevent Uncoordinated Sloughing IV. Management Switch to containing pill Avoid when is contraindicated (e.g. users over age 35 years) Limit to no more than 35 mcg Lower is not associated with bleeding acetate ( ) 10 mg oral daily for 10-14 days per month (Aygestin) Dose: 5 mg PO tid cycle days 15 to 25 Micronized (Prometrium) Dose: 200 mg PO qd

2018 FP Notebook

2. Metrorrhagia Management

Metrorrhagia Management Metrorrhagia Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Metrorrhagia Management Metrorrhagia (...) Management Aka: Metrorrhagia Management , Anovulatory Bleeding Management From Related Chapters II. Indication ( ) III. Goal: Correct Unopposed Estrogen Prevent Prevent Uncoordinated Sloughing IV. Management Switch to containing pill Avoid when is contraindicated (e.g. users over age 35 years) Limit to no more than 35 mcg Lower is not associated with bleeding acetate ( ) 10 mg oral daily for 10-14 days per month (Aygestin) Dose: 5 mg PO tid cycle days 15 to 25 Micronized (Prometrium) Dose: 200 mg PO qd

2015 FP Notebook

3. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS)

International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS) International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018Publication approval The guideline recommendations on pages 16 to 34 of this document were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 2 July 2018 under section 14A of the National Health and Medical Research Council Act 1992 (...) in unaltered form only (retaining this notice) for your personal, non-commercial use, or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. Copies of the guideline can be downloaded from monash.edu/medicine/sphpm/mchri/pcos. Suggested citation: International evidence- based guideline for the assessment and management of polycystic ovary syndrome. Copyright Monash University, Melbourne Australia 2018. Publication history Original

2018 European Society of Human Reproduction and Embryology

4. Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation

Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation (MAVUFERT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03656211 Recruitment Status : Completed First Posted : September 3, 2018 Last Update Posted : September 3, 2018 Sponsor: Rennes

2018 Clinical Trials

5. Comparison Between D&C and Hysteroscopy in Management of AUB in Perimenopausal Women

Comparison Between D&C and Hysteroscopy in Management of AUB in Perimenopausal Women Comparison Between D&C and Hysteroscopy in Management of AUB in Perimenopausal Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Comparison Between D&C and Hysteroscopy in Management of AUB in Perimenopausal Women The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02705222 Recruitment Status : Completed First Posted : March 10, 2016 Last Update Posted : October 29, 2018 Sponsor: Mohamed Sayed Abdelhafez Information

2016 Clinical Trials

6. Practical aspects of the two FIGO systems for management of abnormal uterine bleeding in the reproductive years. (PubMed)

Practical aspects of the two FIGO systems for management of abnormal uterine bleeding in the reproductive years. The FIGO systems defining the nomenclature and symptoms of abnormal uterine bleeding (AUB) in the reproductive years (System 1) and the PALM-COEIN classification of causes of AUB (System 2) are designed to facilitate research, education, and the provision of optimum clinical care for affected women. Development of these systems has been the result of a collaborative effort of experts (...) in bench and translational and clinical research from six continents aided by a spectrum of representatives from relevant medical societies, journals, and regulatory bodies. Integral to this development has been a decision to cease the use of poorly defined and inconsistently used terms such as menorrhagia, metrorrhagia, and dysfunctional uterine bleeding, to name a few, and replace them with a set of terms and definitions that are relatively easily understood and translated into the spectrum

2016 Best practice & research. Clinical obstetrics & gynaecology

7. The Management of Dysfunctional Uterine Bleeding (PubMed)

The Management of Dysfunctional Uterine Bleeding 13278735 2003 05 01 2018 12 01 0027-9684 48 1 1956 Jan Journal of the National Medical Association J Natl Med Assoc The management of dysfunctional uterine bleeding. 41-3 DIGNAM W J WJ eng Journal Article United States J Natl Med Assoc 7503090 0027-9684 OM Disease Management Female Humans Menorrhagia therapy Metrorrhagia therapy 5629:30876 MENORRHAGIA AND METRORRHAGIA/therapy 1956 1 1 1956 1 1 0 1 1956 1 1 0 0 ppublish 13278735 PMC2641171 Am J

Full Text available with Trip Pro

1956 Journal of the National Medical Association

8. CRACKCAST E121 – Anemia, Polycythemia, and White Blood Cell Disorders

History Nature and time of injury Estimated blood loss Non-trauma History Skin: petechiae, bruising Respiratory: hemoptysis, epistaxis Gastrointestinal: hematemesis, hematochezia, melena, peptic ulcer Genitourinary: LMP, menorrhagia (bleeding in-between expected periods), metrorrhagia (excessive bleeding during periods), hematuria Physical Exam Serial Vital signs (including orthostatic vitals), level/content of consciousness Skin: pallor (conjunctival, palmar creases highest LHR), diaphoresis (...) sequestration, cholestasis Gallbladder – increased bilirubin gallstone production Spleen – acute sequestration Urinary – hematuria, hyposthenuria Genital – decreased fertility, impotence, priapism Skeletal – bone infarcts, osteomyelitis, aseptic necrosis Placenta – insufficiency with fetal wastage Leukocytes – relative immunodeficiency Erythrocytes – chronic hemolysis [21] Describe the management of a sickle cell pain crisis Acute: analgesia (patient dependent/directed) with opioids +/- NSAIDS Chronic

2017 CandiEM

9. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline

be compelling reasons to initiate sex hormone treatment prior to age 16 years, although there is minimal published experience treating prior to 13.5 to 14 years of age. For the care of peripubertal youths and older adolescents, we recommend that an expert multidisciplinary team comprised of medical professionals and mental health professionals manage this treatment. The treating physician must confirm the criteria for treatment used by the referring mental health practitioner and collaborate with them (...) 13.5 to 14 years. As with the care of adolescents ≥16 years of age, we recommend that an expert multidisciplinary team of medical and MHPs manage this treatment. (1 |⊕○○○) 2.6. We suggest monitoring clinical pubertal development every 3 to 6 months and laboratory parameters every 6 to 12 months during sex hormone treatment. (2 |⊕⊕○○) 3.0 Hormonal therapy for transgender adults 3.1. We recommend that clinicians confirm the diagnostic criteria of GD/gender incongruence and the criteria

Full Text available with Trip Pro

2017 Pediatric Endocrine Society

13. Baricitinib (Olumiant) - rheumatoid arthritis

by the CHMP with all information of a commercially confidential nature deleted. EMA/13493/2017 Page 2/132 Table of contents 1. Background information on the procedure 9 1.1. Submission of the dossier 9 1.2. Steps taken for the assessment of the product 10 2. Scientific discussion 11 2.1. Problem statement 11 2.1.1. Disease or condition 11 2.1.2. Epidemiology 11 2.1.3. Clinical presentation 11 2.1.4. Management 11 2.1.5. Introduction 15 2.1.6. Active Substance 16 2.1.7. Finished Medicinal Product 19 2.1.8 (...) . Introduction 44 2.3.2. Pharmacokinetics 48 2.3.3. Pharmacodynamics 53 2.3.4. Discussion on clinical pharmacology 57 2.3.5. Conclusions on clinical pharmacology 59 2.4. Clinical efficacy 60 2.4.1. Dose response studies 60 2.4.2. Main studies 60 Clinical studies in special populations 82 2.4.3. Discussion on clinical efficacy 82 2.4.4. Conclusions on the clinical efficacy 85 2.5. Clinical safety 85 2.5.1. Discussion on clinical safety 108 2.5.2. Conclusions on the clinical safety 111 2.6. Risk Management

2017 European Medicines Agency - EPARs

14. Tadalafil - Pulmonary Hypertension

2.4.4. Post marketing experience 23 2.4.5. Discussion on clinical aspects 23 2.4.6. Conclusions on clinical aspects 24 2.5. Risk management plan 24 2.6. PSUR submission 25 2.7. Pharmacovigilance 25 2.8. Product information 25 2.8.1. User consultation 25 3. Benefit-risk balance 25 4. Recommendation 26 EMA/803097/2016 Page 3/26 List of abbreviations 6MWT 6-minute walk test ADR Adverse Drug Reaction AE Adverse event AESI AEs of special interest ALK1 Activin receptor-like kinase type 1 ALP Alkaline (...) of 80.00-125.00%. EMA/803097/2016 Page 24/26 2.4.6. Conclusions on clinical aspects A summary of the literature with regard to clinical data of tadalafil and two bioequivalence studies were provided to demonstrate that the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product and was accepted by the CHMP. 2.5. Risk management plan Safety concerns Summary of safety concerns Important identified risks • Priapism (MedDRA PT: Priapism

2017 European Medicines Agency - EPARs

15. Diagnostic Tests in the Context of Threatened Preterm Labour

Diagnostic Tests in the Context of Threatened Preterm Labour Diagnostic Tests in the Context of Threatened Preterm Labour - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Diagnostic Tests in the Context (...) of the tests will be masked for the clinician and the patient in order to assess and compare their ability to predict delivery within 7 days without modify the current medical management. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 220 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Diagnostic Official Title: Combined Detection

2018 Clinical Trials

16. Phase 1A Safety Trial of Inhaled PK10571

Phase 1A Safety Trial of Inhaled PK10571 Phase 1A Safety Trial of Inhaled PK10571 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Phase 1A Safety Trial of Inhaled PK10571 The safety and scientific validity (...) the study treatment. History of bleeding disorder or coagulopathy. Females with history of dysfunctional uterine bleeding, including history of menorrhagia or metrorrhagia, unless subject has had a hysterectomy. History of GI bleed. Has used any over-the-counter (OTC) medication, nutritional or dietary supplements, herbal preparations, or vitamins within 7 days prior to the first dose of medication. Has used any antiplatelet agents such as acetylsalicylic acid (ASA), nonsteroidal anti-inflammatory drugs

2018 Clinical Trials

17. Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women.

Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women. Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) ovarian reserve test (i.e. AFC < 5 follicles) at screening. Abnormal metrorrhagia due to unknown reason at screening. At least one of husband and wife to accept donor sperm or donor eggs or PGD subject Subjects who are positive for HIV or syphilis at screening. Significant known psychiatric disorder or who unable to understand the objectives and methods, etc. of this clinical trial and unable to comply with the study procedures at screening. Presence of elicit alcohol, smoke or drug abuse habit

2018 Clinical Trials

18. Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis

Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) as the person with a reduction of intensity of at least one level for all symptoms of at least mild intensity at baseline (i.e. from severe to moderate, from moderate to mild, from mild to none). Severity of disease symptom metrorrhagia (none-mild-moderate-severe) [ Time Frame: On the day of the last injection (up to Month 5) ] A full responder is defined as the person with a reduction of intensity of at least one level for all symptoms of at least mild intensity at baseline (i.e. from severe to moderate

2018 Clinical Trials

19. Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled Trial

Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled Trial Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) and mortality. It is estimated that premature births to 15 million worldwide in 2010, including 60,000 children in France (7,4% of births) and 12000, born before 32 weeks of amenorrhea (term defining great prematurity). More than half of these births follow spontaneous work. Before 34 weeks of amenorrhea, prematurity requires specific maternal-fetal management centered primarily on antenatal corticosteroid treatment for fetal maturation including 2 intramuscular injections at 24 hour intervals. This cure

2018 Clinical Trials

20. Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain

. The cost of the combined oral contraceptive medication was zero to the health system because it was paid by patients. The resource use was from a panel of Spanish experts with experience in the management of dysfunctional uterine bleeding. The costs were estimated using the eSalud database, which collected costs from the literature, and using tariffs from national and regional health services. They were in Euros (EUR) and were discounted at an annual rate of 3%. The price year was 2008. Analysis (...) of dysfunctional uterine bleeding in Spain. European Journal of Obstetrics and Gynecology and Reproductive Biology 2011; 154(1): 71-80 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Contraceptive Agents, Female /administration & Contraceptives, Oral, Combined /economics /therapeutic use; Cost-Benefit Analysis; Female; Humans; Intrauterine Devices, Medicated /economics; Levonorgestrel /administration & Metrorrhagia /drug therapy; Models, Theoretical; Progestins /economics

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>